Literature DB >> 15931504

Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy.

W Poller1, U Kühl, C Tschoepe, M Pauschinger, H Fechner, H-P Schultheiss.   

Abstract

Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by impaired contractility and dilation of the ventricles. In a subset of DCM patients, classical inheritance patterns occur (familial DCM), which have led to the identification of specific genomic loci and gene defects causing monogenic DCM subtypes. In the majority of DCM patients, however, there is no evidence for a monogenic etiology of the disorder (sporadic DCM), and in the absence of other recognizable etiological factors, these cases were classified as "idiopathic". Recent research suggests that cardiotropic viruses are important environmental factors in the pathogenesis of "idiopathic" cases and that DCM commonly results from interactions between genetic and environmental factors, whereas "pure" genetic forms are rather rare. Regarding genetics, the clinical cardiomyopathic phenotype associated with single gene defects may be highly variable for unknown reasons. Furthermore, a novel class of genetic defects was identified recently which provide a molecular basis for abnormal reactions of cardiomyocytes to environmental stress. These defects are paradigms of specific molecular links between genome and environment during the pathogenesis of DCM. Regarding environmental factors, a recent molecular virological study based on myocardial biopsies in a large series of sporadic DCM patients has detected cardiac viral infections in the majority of patients, with a broad spectrum of virus species being involved. Apparently, DCM does not only occur as a late sequela of acute viral myocarditis, but also in patients without clinical history of cardiac viral disease. Cardiotropic viruses thus emerge as prevalent environmental factors which may cause or influence the course of DCM in a large fraction of cases. Synopsis of current data suggests that a comprehensive picture of DCM pathogenesis can only be drawn if both genetic and environmental pathogenetic factors are considered. The course of cardiac viral infections depends strongly on genetic host factors and may range from rapid and complete virus elimination or silencing without clinical symptoms, to rapidly progressive or fatal disease. Viruses interact not only with genetically heterogenous host systems of virus uptake, migration, and antiviral immunity, but, due to their prevalence in DCM hearts, are also likely to encounter multiple structural proteins of cardiac cells known to be defective in familial DCM. The combined knowledge on DCM-associated gene defects and viruses therefore suggests in-depth studies on genome-environment interactions in DCM pathogenesis which may underlie the high clinical variability observed both in monogenic and virus-associated DCM and have implications for the clinical management of DCM patients.

Entities:  

Mesh:

Year:  2005        PMID: 15931504     DOI: 10.1007/s00109-005-0664-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  71 in total

1.  First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy.

Authors:  B Hoffmann; H Schmidt-Traub; A Perrot; K J Osterziel; R Gessner
Journal:  Hum Mutat       Date:  2001-06       Impact factor: 4.878

2.  Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis.

Authors:  M S Horwitz; A La Cava; C Fine; E Rodriguez; A Ilic; N Sarvetnick
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

3.  Actin mutations in dilated cardiomyopathy, a heritable form of heart failure.

Authors:  T M Olson; V V Michels; S N Thibodeau; Y S Tai; M T Keating
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

Review 4.  Cardiomyopathies: from genetics to the prospect of treatment.

Authors:  W M Franz; O J Müller; H A Katus
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

5.  Heterozygous inactivation of the vinculin gene predisposes to stress-induced cardiomyopathy.

Authors:  Alice E Zemljic-Harpf; Sornya Ponrartana; Roy T Avalos; Maria C Jordan; Kenneth P Roos; Nancy D Dalton; Vinh Q Phan; Eileen D Adamson; Robert S Ross
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

6.  Missense mutations in desmin associated with familial cardiac and skeletal myopathy.

Authors:  L G Goldfarb; K Y Park; L Cervenáková; S Gorokhova; H S Lee; O Vasconcelos; J W Nagle; C Semino-Mora; K Sivakumar; M C Dalakas
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

7.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson; J Carlson; R Velez
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

Review 8.  Familial hypertrophic cardiomyopathy: from mutations to functional defects.

Authors:  G Bonne; L Carrier; P Richard; B Hainque; K Schwartz
Journal:  Circ Res       Date:  1998-09-21       Impact factor: 17.367

9.  Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens.

Authors:  Sabine Pankuweit; R Moll; U Baandrup; Irene Portig; Günter Hufnagel; Bernhard Maisch
Journal:  Hum Pathol       Date:  2003-05       Impact factor: 3.466

10.  Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy.

Authors:  Jens Mogensen; Ross T Murphy; Tony Shaw; Ajay Bahl; Charles Redwood; Hugh Watkins; Margaret Burke; Perry M Elliott; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2004-11-16       Impact factor: 24.094

View more
  12 in total

Review 1.  Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration.

Authors:  Marten Szibor; Jochen Pöling; Henning Warnecke; Thomas Kubin; Thomas Braun
Journal:  Cell Mol Life Sci       Date:  2013-12-10       Impact factor: 9.261

Review 2.  Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Authors:  Wolfgang Poller; Roger Hajjar; Heinz-Peter Schultheiss; Henry Fechner
Journal:  Cardiovasc Res       Date:  2010-02-22       Impact factor: 10.787

Review 3.  [Classification, genetic predisposition and risk factors for the development of cardiomyopathies].

Authors:  S Pankuweit; A Richter; V Ruppert; R Funck; B Maisch
Journal:  Internist (Berl)       Date:  2008-04       Impact factor: 0.743

4.  Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy.

Authors:  Heinz-Peter Schultheiss; Cornelia Piper; Olaf Sowade; Finn Waagstein; Joachim-Friedrich Kapp; Karl Wegscheider; Georg Groetzbach; Matthias Pauschinger; Felicitas Escher; Eloisa Arbustini; Harald Siedentop; Uwe Kuehl
Journal:  Clin Res Cardiol       Date:  2016-04-25       Impact factor: 5.460

5.  Multigenic Disease and Bilineal Inheritance in Dilated Cardiomyopathy Is Illustrated in Nonsegregating LMNA Pedigrees.

Authors:  Jason R Cowan; Daniel D Kinnamon; Ana Morales; Lorien Salyer; Deborah A Nickerson; Ray E Hershberger
Journal:  Circ Genom Precis Med       Date:  2018-07

6.  Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets.

Authors:  F Wittchen; L Suckau; H Witt; C Skurk; D Lassner; H Fechner; I Sipo; U Ungethüm; P Ruiz; M Pauschinger; C Tschope; U Rauch; U Kühl; H-P Schultheiss; W Poller
Journal:  J Mol Med (Berl)       Date:  2006-11-15       Impact factor: 4.599

7.  Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD.

Authors:  Wenxiang Tang; Zhenyu Shen; Jiang Guo; Shenghua Sun
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-11-28

Review 8.  New therapeutics targets in chronic viral cardiomyopathy.

Authors:  W Poller; H Fechner; U Kühl; M Pauschinger; H P Schultheiss
Journal:  Ernst Schering Res Found Workshop       Date:  2006

Review 9.  Dilated cardiomyopathy.

Authors:  Heinz-Peter Schultheiss; DeLisa Fairweather; Alida L P Caforio; Felicitas Escher; Ray E Hershberger; Steven E Lipshultz; Peter P Liu; Akira Matsumori; Andrea Mazzanti; John McMurray; Silvia G Priori
Journal:  Nat Rev Dis Primers       Date:  2019-05-09       Impact factor: 65.038

10.  The Finnish Cardiovascular Study (FINCAVAS): characterising patients with high risk of cardiovascular morbidity and mortality.

Authors:  Tuomo Nieminen; Rami Lehtinen; Jari Viik; Terho Lehtimäki; Kari Niemelä; Kjell Nikus; Mari Niemi; Janne Kallio; Tiit Kööbi; Väinö Turjanmaa; Mika Kähönen
Journal:  BMC Cardiovasc Disord       Date:  2006-03-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.